Front Genet, 2019, 9(JAN):717

FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier.

Here, we propose a heuristic technique of data trimming for SVM termed FLOating Window Projective Separator (FloWPS), tailored for personalized predictions based on molecular data. This procedure can operate with high throughput genetic datasets like gene expression or mutation profiles. Its application prevents SVM from extrapolation by excluding non-informative features. FloWPS requires training on the data for the individuals with known clinical outcomes to create a clinically relevant classifier. The genetic profiles linked with the outcomes are broken as usual into the training and validation datasets. The unique property of FloWPS is that irrelevant features in validation dataset that don't have significant number of neighboring hits in the training dataset are removed from further analyses. Next, similarly to the k nearest neighbors (kNN) method, for each point of a validation dataset, FloWPS takes into account only the proximal points of the training dataset. Thus, for every point of a validation dataset, the training dataset is adjusted to form a floating window. FloWPS performance was tested on ten gene expression datasets for 992 cancer patients either responding or not on the different types of chemotherapy. We experimentally confirmed by leave-one-out cross-validation that FloWPS enables to significantly increase quality of a classifier built based on the classical SVM in most of the applications, particularly for polynomial kernels.

Tkachev V, Sorokin M, Mescheryakov A, Simonov A, Garazha A, Buzdin A, Muchnik I, Borisov N

IBCH: 7557
Ссылка на статью в журнале: https://www.frontiersin.org/article/10.3389/fgene.2018.00717/full
Кол-во цитирований на 02.2024: 17
Данные статьи проверены модераторами 2019-01-15

Список научных проектов, где отмечена публикация

  1. Выявление факторов, препятствующих успешной HER-таргетной терапии при раке молочной железы и разработка противоопухолевого препарата, связывающего HER-лиганды (6 Января 2018 года — 31 Декабря 2022 года). Буздин А.А.. Грант, РНФ.